Ehlers-Danlos Syndrome National Diagnostic Service, Sheffield Children's Hospital NHS Foundation Trust, OPD2 Department, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK.
Health Economics and Decision Science, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.
Eur J Hum Genet. 2023 Jul;31(7):749-760. doi: 10.1038/s41431-023-01343-7. Epub 2023 Mar 29.
The UK National Diagnostic Service for Ehlers-Danlos Syndromes (EDS) was established in 2009 for the rare types of EDS. Vascular EDS (vEDS) is an inherited connective tissue disorder caused by pathogenic variants in the COL3A1 gene. Associated tissue fragility affects multiple organ systems, increasing the risk of blood vessel dissection and rupture, with potentially fatal consequences. The diagnosis of vEDS has improved with advances in genetic testing, however this is most often suspected following an acute event. We provide data on the clinical features of vEDS for 180 patients (full cohort) seen in our service with confirmed molecular diagnoses. Increased awareness of this rare condition will prompt genetic testing essential to confirm the diagnosis. Outcomes are improved by early diagnosis followed by appropriate management. Fragile connective tissues make invasive procedures potentially dangerous, particularly in an emergency setting. Lifestyle advice from a young age can help acceptance and understanding of the diagnosis and inform choices. There is currently limited evidence for the use of drug therapy to reduce vascular events. We report on the incidence of vascular events in 126 patients (statistical analysis cohort) in our care and the use of medication. Our retrospective data showed that those patients on a long-term angiotensin II receptor blocker and/or beta-blocker had fewer vascular events than those not on cardiac medication who received the same lifestyle and emergency care advice.
英国国家 Ehlers-Danlos 综合征诊断服务(EDS)于 2009 年为罕见类型的 EDS 设立。血管型 EDS(vEDS)是一种遗传性结缔组织疾病,由 COL3A1 基因的致病性变异引起。相关的组织脆弱性影响多个器官系统,增加了血管夹层和破裂的风险,可能导致致命后果。随着基因检测的进步,vEDS 的诊断有所改善,但通常是在急性事件发生后怀疑该病。我们为在我们的服务中看到的 180 名经分子诊断证实的 vEDS 患者(全部队列)提供了临床特征数据。提高对这种罕见疾病的认识将促使进行基因检测以确认诊断。早期诊断和适当的管理可以改善预后。脆弱的结缔组织使侵入性手术具有潜在危险,特别是在紧急情况下。从小就提供生活方式建议可以帮助患者接受和理解诊断,并为他们提供选择。目前,药物治疗减少血管事件的证据有限。我们报告了在我们的护理中 126 名患者(统计分析队列)的血管事件发生率和药物使用情况。我们的回顾性数据显示,长期使用血管紧张素 II 受体阻滞剂和/或β受体阻滞剂的患者比未服用心脏药物但接受相同生活方式和急救护理建议的患者发生血管事件的次数更少。